Akero Therapeutics, Inc. (AKRO)
AKRO Stock Price Chart
Explore Akero Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze AKRO price movements and trends.
AKRO Company Profile
Discover essential business fundamentals and corporate details for Akero Therapeutics, Inc. (AKRO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
20 Jun 2019
Employees
69.00
Website
https://www.akerotx.comCEO
Andrew Cheng
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
AKRO Financial Timeline
Browse a chronological timeline of Akero Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 26 Feb 2026
Upcoming earnings on 14 Nov 2025
EPS estimate is -$0.94.
Earnings released on 8 Aug 2025
EPS came in at -$0.86 surpassing the estimated -$0.97 by +11.34%.
Earnings released on 12 May 2025
EPS came in at $0.90 surpassing the estimated -$1.01 by +189.11%.
Earnings released on 28 Feb 2025
EPS came in at -$0.99 falling short of the estimated -$0.98 by -1.02%.
Earnings released on 8 Nov 2024
EPS came in at -$1.05 falling short of the estimated -$0.90 by -16.67%.
Earnings released on 9 Aug 2024
EPS came in at -$0.81 surpassing the estimated -$0.90 by +10.00%.
Earnings released on 10 May 2024
EPS came in at -$0.90 matching the estimated -$0.90.
Earnings released on 29 Feb 2024
EPS came in at -$0.99 falling short of the estimated -$0.82 by -20.73%, while revenue for the quarter reached $284.00K .
Earnings released on 13 Nov 2023
EPS came in at -$0.71 falling short of the estimated -$0.69 by -2.90%.
Earnings released on 11 Aug 2023
EPS came in at -$0.60 surpassing the estimated -$0.62 by +3.23%.
Earnings released on 15 May 2023
EPS came in at -$0.55 surpassing the estimated -$0.62 by +11.29%.
Earnings released on 17 Mar 2023
EPS came in at -$0.49 surpassing the estimated -$0.78 by +37.18%.
Earnings released on 4 Nov 2022
EPS came in at -$0.92 falling short of the estimated -$0.73 by -26.03%.
Earnings released on 4 Aug 2022
EPS came in at -$0.77 surpassing the estimated -$0.85 by +9.41%.
Earnings released on 6 May 2022
EPS came in at -$0.74 surpassing the estimated -$0.85 by +12.94%.
Earnings released on 25 Feb 2022
EPS came in at -$0.93 falling short of the estimated -$0.81 by -14.81%.
Earnings released on 12 Nov 2021
EPS came in at -$0.70 surpassing the estimated -$0.91 by +23.08%.
Earnings released on 13 Aug 2021
EPS came in at -$0.83 falling short of the estimated -$0.72 by -15.28%.
Earnings released on 13 May 2021
EPS came in at -$0.43 surpassing the estimated -$1.01 by +57.43%.
Earnings released on 16 Mar 2021
EPS came in at -$0.86 falling short of the estimated -$0.72 by -19.44%.
Earnings released on 12 Nov 2020
EPS came in at -$0.63 falling short of the estimated -$0.48 by -31.25%.
AKRO Stock Performance
Access detailed AKRO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.